aiqbench takeAI Products

This partnership highlights a critical business model shift in AI-driven biotech, where companies are trading access to proprietary datasets for foundational models rather than relying solely on discretionary fees. The deal underscores the growing economic value of RNA foundation models like TxFM and the strategic importance of securing long-term data licenses for training advanced machine learning systems.

Sources coveringQuantum Zeitgeist, LessWrong

What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

Recursion commits $42 million to Tempus data partnership

Quantum ZeitgeistSeptember 21, 20262 min read

Recursion Pharmaceuticals will pay Tempus $42 million over three years under an amended data license. Separately, Tempus will pay Recursion $12 million over two years to license Recursion's TxFM RNA foundation model.

Recursion Pharmaceuticals will pay Tempus $42 million over the next three years under a data license agreement. The companies extended their data partnership, first signed in 2023, through November 2029, and…

Excerpt shown under the publisher's RSS terms · 31 words · full text and figures are on the publisher's site

Read at Quantum Zeitgeist ↗Ask about this article